|
Acquired RB1 mutations in estrogen receptor-positive (ER+) clinically advanced and metastatic breast cancer (MBC). |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Roche |
|
|
Employment - Foundation Medicine |
|
|
Stock and Other Ownership Interests - Roche |
|
|
Employment - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine; Roche |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Roche |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine; Partners Healthcare |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine (Inst) |
|
|
Employment - Foundation Medicine |
|
|
Employment - Roche/Foundation Medicine |
Stock and Other Ownership Interests - Roche |
Patents, Royalties, Other Intellectual Property - Patent on IHC |
|
|
No Relationships to Disclose |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
Travel, Accommodations, Expenses - Foundation Medicine |
|
|
No Relationships to Disclose |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine; Roche |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Roche |
Research Funding - Celgene (Inst); Lilly (Inst); Puma Biotechnology (Inst) |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
Consulting or Advisory Role - Celsius Therapeutics |
Research Funding - Foundation Medicine |